Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
2001 3
2002 4
2003 6
2004 14
2005 13
2006 13
2007 6
2008 10
2009 9
2010 4
2011 3
2012 2
2013 2
2014 3
2015 2
2016 2
2017 1
2018 2
2020 0
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 14747371

96 results
Results by year
Filters applied: . Clear all
Page 1
N-acetylcysteine in the prevention of radiocontrast-induced nephropathy.
Fishbane S, Durham JH, Marzo K, Rudnick M. Fishbane S, et al. J Am Soc Nephrol. 2004 Feb;15(2):251-60. doi: 10.1097/01.asn.0000107562.68920.92. J Am Soc Nephrol. 2004. PMID: 14747371 Free article. Review.
Acetylcysteine for radiocontrast nephropathy.
Tepel M, Zidek W. Tepel M, et al. Curr Opin Crit Care. 2001 Dec;7(6):390-2. doi: 10.1097/00075198-200112000-00004. Curr Opin Crit Care. 2001. PMID: 11805540 Review.
Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review.
Walker PD, Brokering KL, Theobald JC. Walker PD, et al. Pharmacotherapy. 2003 Dec;23(12):1617-26. doi: 10.1592/phco.23.15.1617.31958. Pharmacotherapy. 2003. PMID: 14695041 Review.
N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best?
Shalansky SJ, Vu T, Pate GE, Levin A, Humphries KH, Webb JG. Shalansky SJ, et al. Pharmacotherapy. 2005 Aug;25(8):1095-103. doi: 10.1592/phco.2005.25.8.1095. Pharmacotherapy. 2005. PMID: 16207100 Review.
A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and N-acetylcysteine.
Lepor NE. Lepor NE. Rev Cardiovasc Med. 2003;4 Suppl 1:S15-20. Rev Cardiovasc Med. 2003. PMID: 12556733 Review.
N-acetylcysteine and sodium bicarbonate versus N-acetylcysteine and standard hydration for the prevention of radiocontrast-induced nephropathy following coronary angiography.
Schmidt P, Pang D, Nykamp D, Knowlton G, Jia H. Schmidt P, et al. Ann Pharmacother. 2007 Jan;41(1):46-50. doi: 10.1345/aph.1H354. Epub 2006 Dec 26. Ann Pharmacother. 2007. PMID: 17190844
N-acetylcysteine use to prevent contrast medium-induced nephropathy: premature phase III trials.
Stenstrom DA, Muldoon LL, Armijo-Medina H, Watnick S, Doolittle ND, Kaufman JA, Peterson DR, Bubalo J, Neuwelt EA. Stenstrom DA, et al. J Vasc Interv Radiol. 2008 Mar;19(3):309-18. doi: 10.1016/j.jvir.2007.11.003. J Vasc Interv Radiol. 2008. PMID: 18295688 Review.
N-acetylcysteine in the prevention of radiocontrast-induced nephropathy: clinical trials and end points.
Hoffmann U, Banas B, Fischereder M, Krämer BK. Hoffmann U, et al. Kidney Blood Press Res. 2004;27(3):161-6. doi: 10.1159/000079804. Epub 2004 Jul 13. Kidney Blood Press Res. 2004. PMID: 15256811 Free article. Review.
Acetylcysteine and contrast media nephropathy.
Tepel M, Zidek W. Tepel M, et al. Curr Opin Nephrol Hypertens. 2002 Sep;11(5):503-6. doi: 10.1097/00041552-200209000-00005. Curr Opin Nephrol Hypertens. 2002. PMID: 12187314 Review.
Effects of N-acetylcysteine on renal hemodynamics in contrast media-induced nephropathy.
Krzossok S, Braun C, Weiss E, Hoeger S, Schnuelle P, Benck U, Birck R, Krämer BK, Göttmann U. Krzossok S, et al. Kidney Blood Press Res. 2011;34(2):125-34. doi: 10.1159/000324168. Epub 2011 Feb 19. Kidney Blood Press Res. 2011. PMID: 21335974 Free article.
96 results
Jump to page
Feedback